Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study reveals tricky platelet swings in blood disorder drug response

NCT ID NCT05876221

Knowledge-focused Sponsor: University of Cologne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked back at 223 people with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab (Cablivi). The drug quickly normalizes platelet counts, but some patients experience a sharp rise then a dip, which might mislead doctors into giving unnecessary extra treatment. The goal was to identify these patterns and help guide safer, more accurate care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Caplacizumab (Cablivi)
What this could lead to
If successful, this could help doctors better interpret platelet counts during caplacizumab treatment, reducing unnecessary therapy adjustments and side effects.
What could go wrong
This is a retrospective analysis, not a controlled trial, so it cannot prove cause and effect. The findings may not apply to all patients or change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

223 people

The number who actually took part.

Started

Oct 2023

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

In this trial will be enclosed iTTP patients treated with caplacizumab from: * the German real-world cohort of iTTP patients treated with caplacizumab in the years 2018 to 2020 , and * the respective TITAN and HERCULES trial cohorts.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of autoimmune thrombotic thrombocytopenic purpura * Treatment with at least a single dose of caplacizumab, either i.v. or s.c. * Male or female patients older than 18 years of age Exclusion Criteria: * Hereditary thrombotic thrombocytopenic purpura

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acquired thrombotic thrombocytopenic purpura are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired thrombotic thrombocytopenic purpura thrombotic thrombocytopenic purpura

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acquired thrombotic thrombocytopenic purpura

Contacts and locations

Locations

  • University Hospital of Cologne

    Cologne, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.